<DOC>
	<DOCNO>NCT01511068</DOCNO>
	<brief_summary>The purpose study evaluate therapeutic efficacy inhale recombinant human GM-CSF individual hereditary Pulmonary Alveolar Proteinosis ( PAP ) due partial dysfunction GM-CSF receptor .</brief_summary>
	<brief_title>Inhaled Granulocyte-Macrophage Colony Stimulating Factor ( GM-CSF ) Hereditary Pulmonary Alveolar Proteinosis ( PAP )</brief_title>
	<detailed_description />
	<mesh_term>Pulmonary Alveolar Proteinosis</mesh_term>
	<criteria>A diagnosis PAP cause biallelic mutation CSF2RA CSF2RB associate impaired GMCSFRalpha GMCSFRbeta function , respectively , result reduce nonzero GMCSF signal Able willing give write informed consent / assent necessary Clinically stable Confirmed diagnosis disorder surfactant production cause biallelic mutation ABCA3 , SFTPB , SFTPC Confirmed diagnosis autoimmune PAP cause high level GMCSF autoantibody Confirmed diagnosis secondary PAP cause underlying clinical disorder know associate development PAP , e.g. , inhalation silica titanium ; myelodysplasia others Treatment investigational agent 3 month prior enrollment History severe allergic anaphylactic reaction GMCSF yeastderived product History asthma reactive airway disease Known active , viral , fungal , mycobacterial , infection A serious medical condition , opinion investigator data safety monitoring committee , would make patient unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>PAP</keyword>
</DOC>